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Recent studies have reported that decreased T cell infil-
trate alone, or co-ordinate with increased macrophage
infiltrate, correlate with decreased survival in a range of
cancers, including patients with pancreatic cancer. Impor-
tantly, in mouse models of pancreatic cancer, therapies
that decrease tumor-associated macrophage infiltrates
improve the response to chemotherapy, matching data in
mammary cancer models. We have previously demon-
strated that immunotherapy with agonistic antibodies to
OX40 was able to remodel tumors, resulting in increased
CD8 infiltrate and as a consequence, decreased macro-
phage infiltrate. Similarly, others have shown that block-
ing antibodies to CTLA-4 result in increased T cell
infiltrate to tumors, both in mouse models and in
patients. We hypothesize that immunotherapies that
remodel the tumor immune environment will increase
the response to chemotherapy.
To test our hypothesis, we used the Panc02 mouse
model of pancreatic adenocarcinoma that forms a highly
chemo- and radio-resistant tumor in immunocompetent
mice, with extensive stromal involvement and diminished
drug penetrance compared to more immunogenic tumors.
We demonstrate that systemic immunotherapy with anti-
OX40 and anti-CTLA4 transiently changed the polariza-
tion of macrophages in tumors as determined by
decreased arginase expression, and delivery of gemcitabine
chemotherapy during the window of changed macrophage
polarization resulted in significantly improved tumor con-
trol and survival. However, we also demonstrate that com-
bination immunotherapy resulted in Th2 differentiation in
tumor-bearing mice, associated with IL-4 production by
activated CD4 T cells, potentially driving the strong
rebound of arginase expression in tumor macrophages at
later time points. Inhibiting IL-4 in vivo improved the effi-
cacy of immunochemotherapy by significantly extending
survival. These data demonstrate that preparative immu-
notherapy is a novel treatment option to improve the effi-
cacy of chemotherapy where the immune environment is
poor, and may increase response rates in cancers with
negative immunology.
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